Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib, durvalumab, and UV1 maintenance trial in BRCA wild-type recurrent ovarian cancer
2024-516327-14-00Phase 2Authorised
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Nov 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Lynparza, Lynparza + Imfinzi and Lynparza + Imfinzi + UV1 + Leukine (3 arms). Primary endpoint: Progression-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
olaparibdurvalumabUV1sargramostim
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-516327-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516327-14-00.